Data Foundry

Drug recalls 2026

Levothyroxine Sodium Tablets USP 150 mcg — Class II drug recall D-0403-2026

Ongoing recall by MACLEODS PHARMA USA, INC, reported 2026-04-01, distributed nationwide. Subpotent Drug

Recall numberD-0403-2026
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmMACLEODS PHARMA USA, INC, Princeton, NJ, United States
Recall initiated2026-02-26
Classified2026-03-24
Reported by FDA2026-04-01
DistributedNationwide (US)
Quantity1,315 bottles
Reason classespotency
NDC33342-0393, 33342-0393-10, 33342-0393-11, 33342-0393-44, 33342-0394, 33342-0394-10, 33342-0394-11, 33342-0394-44, 33342-0395, 33342-0395-10, 33342-0395-11, 33342-0395-44, 33342-0396, 33342-0396-10, 33342-0396-11, 33342-0396-44, 33342-0397, 33342-0397-10, 33342-0397-11, 33342-0397-44, 33342-0398, 33342-0398-10, 33342-0398-11, 33342-0398-44, 33342-0399 and 23 more
Lot numbers16240062A
Expiration dates2026-03

Product

Levothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Princeton, NJ, Manufactured by: Macleods Pharmaceuticals Ltd., Sarigam, Valsad, Guajarat, INDIA NDC 33342-401-44

Reason for recall

Subpotent Drug

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0403-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.